A Multicenter Study to Assess the Effect of Plasma Exchange in Accelerating the Clearance of Natalizumab in Subjects With Multiple Sclerosis (MS).
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2015
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Pharmacokinetics
- Acronyms PLEX
- Sponsors Biogen Idec
- 09 Sep 2009 Actual end date (Oct 2007) added as reported by ClinicalTrials.gov.
- 18 Apr 2008 New trial record.
- 16 Apr 2008 Results will be presented at the 60th Annual Meeting of the American Academy of Neurology.